A Review of Papillary Renal Cell Carcinoma and MET Inhibitors.

• Authors: Katherine Emilie Rhoades Smith, Department of Medicine, Emory University School of Medicine, Atlanta, GA, USA.; Mehmet Bilen, Emory University
• Journal Title: Kidney Cancer
• Volume: Volume 3, Number 3
• Publisher: IOS Press | 2019-11-01, Pages 151-161
• Type of Work: Article | Final Publisher PDF
• Publisher DOI: http://doi.org/10.3233/KCA-190058
• Subjects: Health Sciences, Oncology; Health Sciences, Rehabilitation and Therapy; Biology, Cell; Health Sciences, Immunology
• Keywords: MET; Papillary renal carcinoma; immune-checkpoint inhibitor; kidney cancer; molecularly targeted therapies; non-clear cell renal cell carcinoma; renal cell cancer; Oncology; treatment

Abstract

Papillary renal cell carcinoma (PRCC) is a subtype of renal cell carcinoma (RCC) accounting for approximately 15-20% of cases and further divided into Type 1 and Type 2. Type 1 PRCC tends to have more alterations in the MET tyrosine kinase receptor than Type 2 PRCC. Treatment for RCC patients is based on studies with minimal participation from patients with PRCC; consequently, conventional therapies tend to be less effective for RCC patients with a subtype other than ccRCC (non-ccRCC). Since MET is a known alteration in PRCC, it is potential target for directed therapy. There have been many attempts to develop MET inhibitors for use in solid tumors including PRCC. The following review will discuss the current research regarding MET-targeted therapy, MET inhibitors in clinical trials, and future directions for MET inhibitors in PRCC.